BerGenBio

Report Publication Announcement • Feb 8, 2022

BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST

BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST

Bergen, Norway,8 February 2022?-BerGenBioASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical need,will be announcing its results for thefourthquarter

2021 onWednesday 16 February 2022.

A briefing by BerGenBio's senior management team will take place at 10:00 am CET

via a webcast presentation, followed by a Q&A session.

The live webcast link will be available at www.bergenbio.comin the

Investors/Financial Reports section. A recording will be available shortly after

the webcast has finished.

Thefourthquarter 2021 report and presentation will be available on the Company's

website in the Investors/Financial Reports section from 7:00 am CET the same

day.

-Ends-

Contacts

Martin Olin

Chief Executive Officer, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

Chief FinancialOfficer, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

ConsiliumStrategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer and COVID

-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is

undergoing phase I clinical testing. In parallel, BerGenBio is developing a

potential companion diagnostic test to identify patient populations most likely

to benefit from AXL inhibition: this is expected to facilitate more efficient

registration trials supporting a precision medicine-based commercialisation

strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit? www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies, and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.